Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy...
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Public Symbol
RCPT
Founded Year
2009
Organization Website
receptos.com
Organization Languages
English
Organization Revenue
5900
Current Technologies
outlook
office 365
php 5 3
google analytics
wordpress org
hyrell
Job Functions
Operations
Information Technology
Human Resources
Finance
Engineering
Education
Consulting
Business Development
Support
Administrative
Marketing
ulcerative colitis
biopharmaceutical
multiple sclerosis
biotechnology
biopharma
health care
health
wellness & fitness
Bryanna Paulson's Work History and Education
Receptos, a wholly-owned subsidiary of Celgene
Research Associate
2015 - Present
Colleagues at
Receptos A Whollyowned Subsidiary Of Celgene